Mucolytic Respiratory Products & Inhaled Antibiotics

Mucolytic Respiratory Products

Indication: Cystic Fibrosis

• MOA:This enzyme is delivered by inhalation to assist in the clearance of bronchial secretions due to the inflammatory processes and death of leukocytes, bacteria and tissue large amount of extracellular DNA accumulate.
• The buildup of DNA leads to increased viscosity of sputum. This enzyme has NO EFFECT on intracellular DNA
• The enzyme cleaves the DNA decreasing viscosity improving mucociliary clearance of sputum decreasing recurrent bacterial infections

Do NOT use the same neubulizer for other inhalation medications

Contraindicated: breast feeding, children under 5, and hamster protein sensitivity

Adverse effects-chest pain, cough, dyspnea- disease or actual side effect

must be stored in refrigerator

Mucolytic Respiratory Product

• Indications: adjunctive therapy for abnormal, vicid, or inspissated mucus secretions in chronic bronchopulmonary disease: COPD, asthma, CF, posttraumatic chest conditions, anesthesia, tracheostomy care. 
• Antidote to hepatotoxins including acetaminophen overdosage

MOA: thiol group disrupts the disulfide linkages in mucoproteins causing depolymerization and a drop in viscosity. NO affect on DNA

Inhaled Antibiotic

Indication: treatment of CF patients to improve pulmonary function when they are infected with Pseudomonas aeruginosa. First inhaled antibiotic and useful in resistant strains using specific nebulizer product Altera

MOA: Monobactam-inhibits cell wall crosslinking

inhaled antibiotic

Aminoglycoside Antibiotic